Wellbeing Group

Wellbeing Group is a biotechnology company and investment entity focused on developing novel therapies for chronic inflammatory diseases. The company gained prominence in 2023 through its acquisition of the VB-601 asset and related intellectual property from VBL Therapeutics. Operating primarily through its assignee, ImmuneWalk Therapeutics, the group is advancing its lead candidate, IW-601 (formerly VB-601), a first-in-class monoclonal antibody targeting the MOSPD2 receptor. This proprietary Monocyte Targeting Technology (MTT) is designed to selectively block the migration of monocytes into inflamed tissues, offering a potential disease-modifying approach for conditions such as multiple sclerosis, rheumatoid arthritis, and NASH. The company is led by a team of industry veterans and former executives from VBL Therapeutics.